Vertex is poised for a shopping spree. But it’s still unclear just what might go into their basket — and at least one analyst is getting impatient
After setting the tone at JP Morgan for a busy year of dealmaking, Reshma Kewalramani and her Vertex crew are giving slightly more shape to the pipeline they want to build with $6.7 billion in cash — but leaving much to be speculated.
Through it all, the freshman CEO says, Vertex will remain “a company that is about specialty markets” — and emphatically not a rare disease player.
Geoff Porges at SVB Leerink, though, sees the drive to introduce new drugs to the pipeline more driven by necessity than anything else. The company, according to him, is avoiding key questions while exposing “inconsistencies between their portfolio and their strategy.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.